Literature DB >> 28755977

Plasmas for Treating Cancer: Opportunities for Adaptive and Self-Adaptive Approaches.

Michael Keidar1, Dayun Yan2, Isak I Beilis3, Barry Trink4, Jonathan H Sherman2.   

Abstract

Plasma is an ionized gas that is typically formed under high-temperature laboratory conditions. Recent progress in atmospheric plasmas has led to cold atmospheric plasma (CAP) devices with ion temperatures close to room temperature. The unique chemical and physical properties of CAP have led to its use in various biomedical applications including cancer therapy. CAP exhibits a spontaneous transition from a spatially homogeneous state to a modifiable pattern that is subject to self-organization. In this Opinion article, we discuss some new applications for plasma in cancer therapy based on plasma self-organization, which enables adaptive features in plasma-based therapeutic systems.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28755977     DOI: 10.1016/j.tibtech.2017.06.013

Source DB:  PubMed          Journal:  Trends Biotechnol        ISSN: 0167-7799            Impact factor:   19.536


  27 in total

1.  Cold atmospheric plasma induced genotoxicity and cytotoxicity in esophageal cancer cells.

Authors:  Hanieh Estarabadi; Seyed Alireza Atyabi; Sajjad Tavakkoli; Zahra Noormohammadi; Mohamad Reza Gholami; Ali Ghiaseddin; Shiva Irani
Journal:  Mol Biol Rep       Date:  2021-02-06       Impact factor: 2.316

Review 2.  Medically important biofilms and non-thermal plasma.

Authors:  Jaroslav Julák; Vladimír Scholtz; Eva Vaňková
Journal:  World J Microbiol Biotechnol       Date:  2018-11-19       Impact factor: 3.312

3.  Non-Thermal Plasma-Induced Immunogenic Cell Death in Cancer: A Topical Review.

Authors:  Marian Khalili; Lynsey Daniels; Abraham Lin; Fred C Krebs; Adam E Snook; Sander Bekeschus; Wilbur B Bowne; Vandana Miller
Journal:  J Phys D Appl Phys       Date:  2019-08-06       Impact factor: 3.207

Review 4.  Emerging innovations in cold plasma therapy against cancer: A paradigm shift.

Authors:  Sunil Kumar Dubey; Neha Dabholkar; Udit Narayan Pal; Gautam Singhvi; Navin Kumar Sharma; Anu Puri; Prashant Kesharwani
Journal:  Drug Discov Today       Date:  2022-05-19       Impact factor: 8.369

Review 5.  Primary cold atmospheric plasma combined with low dose cisplatin as a possible adjuvant combination therapy for HNSCC cells-an in-vitro study.

Authors:  Teresa F Brunner; Florian A Probst; Matthias Troeltzsch; Sabina Schwenk-Zieger; Julia L Zimmermann; Gregor Morfill; Sven Becker; Ulrich Harréus; Christian Welz
Journal:  Head Face Med       Date:  2022-06-29       Impact factor: 2.246

6.  Theranostic Potential of Adaptive Cold Atmospheric Plasma with Temozolomide to Checkmate Glioblastoma: An In Vitro Study.

Authors:  Vikas Soni; Manish Adhikari; Li Lin; Jonathan H Sherman; Michael Keidar
Journal:  Cancers (Basel)       Date:  2022-06-25       Impact factor: 6.575

7.  Insight into the Impact of Oxidative Stress on the Barrier Properties of Lipid Bilayer Models.

Authors:  Zahra Nasri; Mohsen Ahmadi; Johanna Striesow; Mehdi Ravandeh; Thomas von Woedtke; Kristian Wende
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

8.  Adaptation of Operational Parameters of Cold Atmospheric Plasma for in Vitro Treatment of Cancer Cells.

Authors:  Eda Gjika; Sonali Pal-Ghosh; Anna Tang; Megan Kirschner; Gauri Tadvalkar; Jerome Canady; Mary Ann Stepp; Michael Keidar
Journal:  ACS Appl Mater Interfaces       Date:  2018-03-06       Impact factor: 9.229

9.  CAP modifies the structure of a model protein from thermophilic bacteria: mechanisms of CAP-mediated inactivation.

Authors:  Pankaj Attri; Jeongmin Han; Sooho Choi; Eun Ha Choi; Annemie Bogaerts; Weontae Lee
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

10.  The Cell Activation Phenomena in the Cold Atmospheric Plasma Cancer Treatment.

Authors:  Dayun Yan; Wenjun Xu; Xiaoliang Yao; Li Lin; Jonathan H Sherman; Michael Keidar
Journal:  Sci Rep       Date:  2018-10-18       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.